Radioligand therapy prostate-specific membrane antigen
Emily MenendezProstate Cancer | June 13, 2024
177Lu-PSMA-617 in heavily pretreated patients with late-stage mCRPC provided beneficial antitumor effects.
Read More
Emily MenendezCRPC | June 13, 2024
Intensified RLT with escalation of the first 3 cycles to 10-11 GBq for high-volume mCRPC may increase treatment efficacy.
Karine Tawagi, MDAdvancements in Oncology | June 12, 2024
Dr. Tawagi opines on whether the high rates of crossover in the PSMAfore control arm limit the applicability of the results.
Zachary BessetteRLT | June 11, 2024
A phase 3 trial offers the first randomized evidence of the benefit of PSMA tandem therapy in patients with mCRPC.
Brandon TwyfordRLT | June 10, 2024
Study shows [177Lu]Lu-PSMA is safe and effective for elderly patients with mCRPC, improving PSA response and overall survival
GU Oncology Now EditorsAdvancements in Oncology | June 13, 2024
Dr. Karine Tawagi focused this part of her discussion on 177Lu-PSMA-617 and the PSMAfore trial updates.
Michael Morris, MDRLT | June 4, 2024
Dr. Morris discusses a phase 1 study of JNJ-6420 for patients with mCRPC who received at least prior ARPI.
Emily MenendezCRPC | May 7, 2024
Previous research has shown that the effects of androgen and PSMA receptors can complement each other if used concurrently.
Zachary BessetteRLT | April 30, 2024
A CR was observed in the first patient with mCRPC to receive 2 cycles of 67Cu-SAR-bisPSMA at a dosage of 8GBq.
Gary Ulaner, MD, PhD, FSNMMI, FACNMProstate Cancer Diagnostics | April 16, 2024
Dr. Ulaner highlights 2 new clinical trials for prostate cancer staging and treatment at Hoag: MIRROR and 177Lu-PNT2002.
Katy MarshallCRPC | March 1, 2024
The open-label VISON study randomly assigned patients to receive either 177Lu-PSMA-617 plus SoC or SoC alone.
Katy MarshallRLT | February 14, 2024
A total of 488 patients received an average of 2 cycles of 225Ac-PSMA RLT between January 2016 and May 2023.
Emily MenendezASCO GU Symposium 2024 | January 27, 2024
The study analyzed VISION-eligible patients with mCRPC who were classified as TheraP-eligible or ineligible.
Emily MenendezASCO GU Symposium 2024 | January 27, 2024
The study is the first large-scale report of patients in the United States treated with 177Lu-PSMA-617.
Amar Kishan, MDRLT | January 24, 2024
Dr. Kishan discusses new research presented at the 2024 PSMA Conference.
Jérémie Calais, MD, PhDRLT | January 24, 2024
The first annual PSMA Conference focused on updates in the field of PSMA-based treatments.
Zachary BessetteRLT | January 19, 2024
Dr. Oliver Sartor presented his high-level “provocateur” thoughts on the optimal time to give PSMA RLT.
Emily MenendezRLT | December 14, 2023
PSA levels were decreased by half in 46.9% of patients, and a decline in CTC count occurred 59.1% of patients.
Zachary BessetteCRPC | December 6, 2023
ASCO has provided a rapid update on its guideline recommendations for 177Lutetium-PSMA-617 in mCRPC.
Oliver Sartor, MDRLT | December 4, 2023
Drs. Wallis and Sartor highlight issues with the control arm and considerations for treatment sequencing related to PSMAfore.